HLA-C and neoplasm: CAR T-cell therapy is conducted on the basis of circulating T-lymphocytes that can subsequently be engineered for expressing CARs; as a result, these T-lymphocytes are capable of recognizing and responding to tumor cells without the need for the major histocompatibility complex (MHC).